More than 80% of the annual report of biomedical industry is expected

Introduction: the pharmaceutical industry is one of the few industries that are not plagued by the slowdown of economic growth in the two cities Data shows that of 58 pharmaceutical companies that have issued performance forecasts, 49 companies have reached 84.48% of the total Analysis shows that as the market's investment hotspot gradually transits from undervalued value to low growth, the pharmaceutical stocks that "ran too slowly" before have the requirement to make up for the rise, and they have been on the "wind tunnel" According to the schedule of scheduled disclosure of annual reports published by Shanghai Stock Exchange and Shenzhen Stock Exchange, the disclosure of 2014 annual reports of listed companies will be officially opened on January 15, that is, this Thursday With the gradual progress of the annual report disclosure, the market focus turns to the China market In this context, the performance of industry and individual stocks has attracted much attention According to statistics, as of January 12, 1079 companies in Shanghai and Shenzhen have issued performance forecasts for 2014 annual report, of which 722 companies have realized the increase in advance, slight increase, profit continuation and loss reversal, and the proportion of expected earnings reached 66.91% From the perspective of the pre growth of individual stocks in the industry, medicine is one of the few industries that are not plagued by the slowdown of economic growth and whose performance continues to maintain an obvious momentum Statistics show that among 58 pharmaceutical and biological industry companies that have issued performance forecast, 49 companies have achieved pre increase, slight increase, profit continuation and loss reversal, and the proportion of pre-gratification is 84.48% In addition, 30 companies have a large increase rate of 30% or more in advance, and more than 50% of Companies in the pharmaceutical and biological industry are expected to have a net profit increase rate of 30% or more in 2014 According to the analysis, although the announcement of China Daily is only the tip of the iceberg, it can still be seen from the inside Generally speaking, if there are multiple companies in the same industry predicting the performance growth at the same time, it has certain representativeness There are many companies in the pharmaceutical and biological industry, indicating that the overall growth of this industry is quite good Industry insiders said in an interview that with the economic development and the improvement of people's living standards, the demand for biomedical products is increasing day by day, and the biomedical industry has a certain growth In addition, with the rapid development of medical reform and the national basic drug system, the total health expenditure will continue to grow rapidly, laying a solid foundation for the development of biomedical industry "In the medium and long term, China's pharmaceutical industry has a huge development space China's medical expenditure is significantly lower than that of developed countries With the development of economy and the improvement of health consciousness, medical expenditure will increase rapidly In addition, the aging population and other reasons will continue to increase the demand of the pharmaceutical industry " The researcher of Anxin Securities pointed out China's aging trend will surely increase the growth space of the pharmaceutical and biological industry Experts predict that by 2025, the number of elderly people over 60 years old will reach 291 million, and by 2050, it is expected to reach 440 million A large number of elderly people will also inject growth power into China's pharmaceutical industry.